The Indian Institute of All India Medicine in Delhi is famous in India and has always enjoyed a good reputation. However, it has recently been involved in a scandal that has caused a sensation in the country.
In response to a question from a U.S. children’s rights protection group, the Udairai Foundation, Dogra’s director admitted that the hospital had conducted clinical drug trials on 4142 infants since January 2006. Of these, 2,728 infants were under the age of 1,49 The infant died in drug trials and "at least five well-known Western pharmaceutical companies conduct infant drug trials in the hospital."
Uday Foundation spokesman Verma said: "Many infant parents complained that their children were only minor problems, but after being sent to the All-Institute of Medical Sciences, they were often told that they needed to be hospitalized for a long time, and many infants would not have the opportunity to leave the hospital again. â€
India is a country where the past, present and future coexist. The proportion of illiterate adults is as high as 39%. Nearly 40% of households still use kerosene lamps. Verma said that the parents of many babies are not well-educated and are easily misled and deceived by so-called professionals. According to the author's understanding, since the All India Medical Academy is a completely free public medical institution, there are indeed many poor people and even illiterate people there. It is not easy for parents of children to clearly understand the consequences of infant drug tests.
This scandal shocked all walks of life in India and people fear that mercenary Western drug companies will use some Indian medical institutions that lack medical ethics to "take shortcuts." India’s ruling Congress Party also issued a statement: “This practice of using infants as experimental products to test drugs must be stopped.â€
However, western pharmaceutical companies and Indian medical institutions have formed a complex interest community in India. It is easier for vulnerable Indian patients to maintain their own interests.
The Indian State Planning Commission official told the author that India has become one of the major human clinical trial sites for Western pharmaceutical companies in Asia. Currently, foreign pharmaceutical companies, mainly Western pharmaceutical companies, are conducting human trials of 139 drugs in India. The reason why these Western companies particularly favor the outsourcing of clinical trials to Indian medical institutions is mainly due to the complexity of the Indian population gene pool and the low cost of such experiments.
India has a population of 1.1 billion and there are enough test subjects. Ethnically speaking, India has whites, yellows, and blacks, and it is an ideal large gene pool that facilitates new drug testing. Many people in India have never used any medicine to treat diseases because of poverty. This will avoid interference between new drugs and old drugs.
More importantly, the cost of clinical trials in India is much lower. For example, recruiting the same level of scientific research personnel in India, the reward is at least half lower than that in Europe and the United States; at the same time, the compensation to Indian subjects and compensation for accidents are very low. According to estimates by the Netherlands Agricultural Cooperation Bank, conducting clinical trials in India can reduce research and development costs by 60%. Some well-known western “think tanks†have also lobbied the Indian government to “provide clinical drug trials as new outsourcing stars like the IT industryâ€. These Western "think tank" institutions have even drawn a "big multibillion-dollar US dollars in human clinical trial outsourcing business in India by 2010".
According to the author's investigation, many medical institutions, including some countries in India and Africa, are actively competing for "orders" for clinical drug trials by Western pharmaceutical companies.
Officials of the Indian State Planning Commission also revealed that the number of personnel currently responsible for the control of human clinical trials in India is as low as 40,000, including pilot survey experts, audit experts, ethic experts and data security management experts. Even the drug trials are responsible for approval. The staff of the Drug Control Department are all seriously deficient. Due to the weak supervision, Western pharmaceutical companies and domestic clinical trial institutions have often taken consideration of interests and tried to obtain test results as soon as possible, resulting in various violations and violations. The All India Academy of Medical Sciences that caused this scandal also had to admit that it is not until now that the hospital has not figured out how many infants who died from the use of experimental drugs, and how many of them belong to the control group. In Western countries, the general principle of human trials is that medical institutions must strictly perform the informed consent procedure and cannot use unfair means such as concealment, deception, inducement, and coercion. Patients have the right to understand the full contents of the diagnosis and treatment process, including possible risks and benefits. The result, the required cost, etc., can also be completely rejected. Because of this, in the United States, only 3% of cancer patients are willing to participate in clinical trials of new drugs. In India, 90% of drug users are helpless poor people. After listening to western pharmaceutical companies and India's domestic "experts" to stir up insults, what can they do in addition to eventually becoming a "white rat" in the interests of the western drug makers and Indian clinical trial institutions? What about other options?
Air Preheaters (APH)
An air preheater (APH) is a device used to heat air, commonly used in industrial boilers, thermal power plants, and other thermal energy facilities. APH improves the thermal efficiency of the boiler by transferring heat from the flue gas to the air entering the boiler through heat exchange with it.
APH usually consists of a Heat Exchanger with a number of parallel pipes inside the exchanger through which smoke and air flow to allow heat exchange. In APH, the smoke flows on the outside of the heat exchanger and the air flows on the inside so that the heat between the smoke and the air can be transferred through the pipe walls.
The main business scope is various heaters, waste heat boilers, pressure vessels, supportingair preheaters, air coolers, furnace accessories and accessories, and provide equipment installation, with EPC ability of projects. At present, our customers have covered all large and medium-sized petrochemical enterprises in China and established long-term strategic cooperative partnership with them. Products are exported to Southeast Asia, Middle East, and other regions.
Air Preheaters,Enameled Air Preheater,Air Preheater Supply,Boiler Air Preheater
Jiangsu Gelan Environmental Technology Co., LTD , https://www.etfiredheater.com